- From: kc28 <kei.cheung@yale.edu>
- Date: Wed, 31 Jan 2007 22:58:09 -0500
- To: kc28 <kei.cheung@yale.edu>
- Cc: June Kinoshita <junekino@media.mit.edu>, donald.doherty@brainstage.com, public-semweb-lifesci@w3.org
Just want to clarify that the ontology should be generic enough to handle different neurological diseases such as AD and PD. Also, it may be possible to integrate the ontology (although it's not OWL-based) into the current bioont effort. Best, -Kei kc28 wrote: > > Hi June, Don, et al, > > As part of the BioRDF's SenseLab task, we have recently created an > RDFS ontology for BrainPharm (a subdatabase of SenseLab). The ontology > can be used to model information about the effect of drugs on > pathological (or molecular) mechanisms (which involve neuronal > properties such as receptors, currents, and neurotransmitters) > mediating the pathological changes in various neurological disorders > such as AD. For more information, please go to the following wiki page: > > http://esw.w3.org/topic/BrainPharm > > I hope this ontology (with modifications/extensions perhaps) may be > useful to the AD use case. > > Best, > > -Kei > > June Kinoshita wrote: > >> >> Thanks Don. I think we'll hunker down with the article for a while, >> and if any questions come up, perhaps she could answer them via >> email. That may be the most efficient way to proceed at this point. >> >> Cheers, >> June >> >> On Jan 31, 2007, at 2:48 PM, Donald Doherty wrote: >> >>> >>> Hi All, >>> >>> Susan Catalano said she'd be happy to join one of the HCLSIG >>> teleconference >>> calls to answer questions about ADDL (if there is still a need). >>> >>> Don >>> >>> ----- >>> Donald Doherty, Ph.D. >>> Brainstage Research, Inc. >>> www.brainstage.com >>> donald.doherty@brainstage.com >>> 412-683-1410 >>> >>> >>> >> >> > >
Received on Thursday, 1 February 2007 04:00:32 UTC